NYSE:AGE

AgeX Therapeutics Stock Forecast, Price & News

$1.40
-0.02 (-1.41 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.38
Now: $1.40
$1.48
50-Day Range
$1.38
MA: $1.80
$2.52
52-Week Range
$0.67
Now: $1.40
$3.93
Volume99,884 shs
Average Volume323,621 shs
Market Capitalization$53.11 million
P/E RatioN/A
Dividend YieldN/A
Beta1.5
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; a collaboration with Sernova Corp.; and a research collaboration with The Ohio State University using AgeX's brown adipocyte tissue cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health, and cardiac function. The company was founded in 2017 and is based in Alameda, California.
AgeX Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone510-671-8370
Employees6
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.73 million
Book Value$0.07 per share

Profitability

Net Income$-12,150,000.00
Net Margins-582.11%

Miscellaneous

Market Cap$53.11 million
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable

Headlines

Where Do Hedge Funds Stand On AgeX Therapeutics, Inc. (AGE)?
November 27, 2020 |  finance.yahoo.com
Juvenescence discloses 50% stake in AgeX Therapeutics
October 8, 2020 |  seekingalpha.com
LCTX Mar 2021 5.000 call
October 1, 2020 |  uk.finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

0.48 out of 5 stars

Medical Sector

1607th out of 2,024 stocks

Pharmaceutical Preparations Industry

672nd out of 771 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$1.40
-0.02 (-1.41 %)
(As of 04/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AGE News and Ratings via Email

Sign-up to receive the latest news and ratings for AGE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AgeX Therapeutics (NYSE:AGE) Frequently Asked Questions

What stocks does MarketBeat like better than AgeX Therapeutics?

Wall Street analysts have given AgeX Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AgeX Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is AgeX Therapeutics' next earnings date?

AgeX Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for AgeX Therapeutics
.

How were AgeX Therapeutics' earnings last quarter?

AgeX Therapeutics, Inc. (NYSE:AGE) issued its quarterly earnings results on Wednesday, March, 31st. The company reported ($0.07) EPS for the quarter. The firm had revenue of $0.51 million for the quarter. AgeX Therapeutics had a negative trailing twelve-month return on equity of 932.89% and a negative net margin of 582.11%.
View AgeX Therapeutics' earnings history
.

How has AgeX Therapeutics' stock price been impacted by Coronavirus?

AgeX Therapeutics' stock was trading at $0.88 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AGE shares have increased by 59.1% and is now trading at $1.40.
View which stocks have been most impacted by COVID-19
.

Who are AgeX Therapeutics' key executives?

AgeX Therapeutics' management team includes the following people:
  • Dr. Michael D. West, Founder, Pres, CEO & Director (Age 68, Pay $561.03k)
  • Ms. Eun-Jae Park C.P.A., Chief Financial Officer (Age 49, Pay $277.35k)
  • Dr. Nafees Naseer Malik M.D., Chief Operating Officer (Age 43, Pay $282.27k)
  • Dr. Ivan Labat, Chief Information Officer
  • Ms. Judith Segall, Sec. (Age 68)

Who are some of AgeX Therapeutics' key competitors?

What other stocks do shareholders of AgeX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AgeX Therapeutics investors own include Biocept (BIOC), Allena Pharmaceuticals (ALNA), Co-Diagnostics (CODX), Moleculin Biotech (MBRX), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), AIM ImmunoTech (AIM), Ampio Pharmaceuticals (AMPE), AzurRx BioPharma (AZRX) and Digital Ally (DGLY).

What is AgeX Therapeutics' stock symbol?

AgeX Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGE."

How do I buy shares of AgeX Therapeutics?

Shares of AGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AgeX Therapeutics' stock price today?

One share of AGE stock can currently be purchased for approximately $1.40.

How much money does AgeX Therapeutics make?

AgeX Therapeutics has a market capitalization of $53.11 million and generates $1.73 million in revenue each year.

How many employees does AgeX Therapeutics have?

AgeX Therapeutics employs 6 workers across the globe.

What is AgeX Therapeutics' official website?

The official website for AgeX Therapeutics is www.agexinc.com.

Where are AgeX Therapeutics' headquarters?

AgeX Therapeutics is headquartered at 965 ATLANTIC AVENUE SUITE 101, ALAMEDA CA, 94501.

How can I contact AgeX Therapeutics?

AgeX Therapeutics' mailing address is 965 ATLANTIC AVENUE SUITE 101, ALAMEDA CA, 94501. The company can be reached via phone at 510-671-8370.


This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.